Pulmonary Complications Secondary to Immune Checkpoint Inhibitors
Background. Immune checkpoint inhibitors (ICI) have changed the landscape in the treatment of a number of cancers. Immune-related adverse events (irAEs) have emerged as a serious clinical problem with the use of ICI. Methods. All oncology patients diagnosed with pulmonary complications secondary to...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2020-01-01
|
| Series: | International Journal of Chronic Diseases |
| Online Access: | http://dx.doi.org/10.1155/2020/4928648 |